Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,646.33
(
-1.04%
)
US TECH 100
23,934.19
(
-0.82%
)
Dow Jones
46,334.17
(
-1.40%
)
Brent Oil
104.76
(
4.08%
)
Bitcoin
71,096.00
(
-3.85%
)
News Focus
News Focus

Replies to post #50371 on Biotech Values

Replies to #50371 on Biotech Values
icon url

DewDiligence

07/30/07 2:32 PM

#50376 RE: masterlongevity #50371

>I'm sure NVS is happy about this. note sarcasm<

Whatever happens with Avastin, NVS is still very happy to have inked a deal for the ex-US commercial rights to Lucentis. It sure beats trying to sell Visudyne.
icon url

DewDiligence

07/30/07 5:35 PM

#50382 RE: masterlongevity #50371

OSIP’s Colin Goddard said on today’s CC that the Eyetech business is still useful for its NOL’s. Maybe he should have said it is useful for its LOL’s.

OSIP now lists the Eyetech business as a “discontinued operation,” which obviates the need for them to disclose how bad the Macugen sales were.